PURPOSE: In cancer treatment trials, clinicians traditionally report patient toxicity symptoms. Alternatively, patients could provide this information directly. PATIENTS AND METHODS: The Common Terminology Criteria for Adverse Events (CTCAE) is the mandated instrument for tracking patient toxicity symptoms in National Cancer Institute (NCI)-sponsored cancer treatment trials. We adapted CTCAE symptom items into patient language and uploaded these to an online platform. Lung cancer outpatients receiving chemotherapy were invited to self-report selected symptoms at visits via waiting area computers or optional home access. Symptom reports were printed for nurses at visits, but no instructions were given with regard to use of this information. RESULTS: From June 2005 through March 2006, 125 patients were invited to participate, and 107 chose to enroll. Mean length of participation was 42 weeks (range, 1 to 71 weeks), by which time 35% died. The average number of clinic visits was 12 (range, 1 to 40 visits). At each consecutive visit, most patients (mean, 78%) logged in without significant attrition. Reasons for failure to log in included having no reminder and having inadequate time. Although 76% of enrollees had home computers, only 15% self-reported from home. Satisfaction with the system was high (90%), but only 51% felt communication was improved. All participating nurses understood the reports and felt this information was useful for clinical decisions, documentation, and discussions. However, only one of seven nurses discussed reports with patients frequently, with insufficient time being the most common barrier to discussions. CONCLUSION: Online patient self-reporting is a feasible long-term strategy for toxicity symptom monitoring during chemotherapy, even among patients with advanced cancer and high symptom burdens. However, without explicit reminders and clinician feedback, patients demonstrated limited voluntary interest in self-reporting between visits.
PURPOSE: In cancer treatment trials, clinicians traditionally report patienttoxicity symptoms. Alternatively, patients could provide this information directly. PATIENTS AND METHODS: The Common Terminology Criteria for Adverse Events (CTCAE) is the mandated instrument for tracking patienttoxicity symptoms in National Cancer Institute (NCI)-sponsored cancer treatment trials. We adapted CTCAE symptom items into patient language and uploaded these to an online platform. Lung cancer outpatients receiving chemotherapy were invited to self-report selected symptoms at visits via waiting area computers or optional home access. Symptom reports were printed for nurses at visits, but no instructions were given with regard to use of this information. RESULTS: From June 2005 through March 2006, 125 patients were invited to participate, and 107 chose to enroll. Mean length of participation was 42 weeks (range, 1 to 71 weeks), by which time 35% died. The average number of clinic visits was 12 (range, 1 to 40 visits). At each consecutive visit, most patients (mean, 78%) logged in without significant attrition. Reasons for failure to log in included having no reminder and having inadequate time. Although 76% of enrollees had home computers, only 15% self-reported from home. Satisfaction with the system was high (90%), but only 51% felt communication was improved. All participating nurses understood the reports and felt this information was useful for clinical decisions, documentation, and discussions. However, only one of seven nurses discussed reports with patients frequently, with insufficient time being the most common barrier to discussions. CONCLUSION: Online patient self-reporting is a feasible long-term strategy for toxicity symptom monitoring during chemotherapy, even among patients with advanced cancer and high symptom burdens. However, without explicit reminders and clinician feedback, patients demonstrated limited voluntary interest in self-reporting between visits.
Authors: Andrew J Vickers; Daniel Sjoberg; Ethan Basch; Frank Sculli; Marwan Shouery; Vincent Laudone; Karim Touijer; James Eastham; Peter T Scardino Journal: Eur Urol Date: 2011-11-04 Impact factor: 20.096
Authors: Hunter Warwick; Carolyn Hutyra; Cary Politzer; Andrew Francis; Thomas Risoli; Cynthia Green; Nikhil Verma; Scott Huettel; Richard C Mather Journal: Clin Orthop Relat Res Date: 2019-07 Impact factor: 4.176
Authors: Ethan Basch; Bryce B Reeve; Sandra A Mitchell; Steven B Clauser; Lori M Minasian; Amylou C Dueck; Tito R Mendoza; Jennifer Hay; Thomas M Atkinson; Amy P Abernethy; Deborah W Bruner; Charles S Cleeland; Jeff A Sloan; Ram Chilukuri; Paul Baumgartner; Andrea Denicoff; Diane St Germain; Ann M O'Mara; Alice Chen; Joseph Kelaghan; Antonia V Bennett; Laura Sit; Lauren Rogak; Allison Barz; Diane B Paul; Deborah Schrag Journal: J Natl Cancer Inst Date: 2014-09-29 Impact factor: 13.506
Authors: Liana D Castel; Katherine E Hartmann; Ingrid A Mayer; Benjamin R Saville; JoAnn Alvarez; Chad S Boomershine; Vandana G Abramson; A Bapsi Chakravarthy; Debra L Friedman; David F Cella Journal: Cancer Date: 2013-04-10 Impact factor: 6.860
Authors: Thomas M Atkinson; Karen Hurley; Carma L Bylund; Alexandra Berk; Kimberly Diminni; Jamie S Ostroff Journal: J Cancer Educ Date: 2013-03 Impact factor: 2.037
Authors: Susan E Yount; Nan Rothrock; Michael Bass; Jennifer L Beaumont; Deborah Pach; Thomas Lad; Jyoti Patel; Maria Corona; Rebecca Weiland; Katherine Del Ciello; David Cella Journal: J Pain Symptom Manage Date: 2013-11-07 Impact factor: 3.612
Authors: Andrew J Vickers; Talya Salz; Ethan Basch; Matthew R Cooperberg; Peter R Carroll; Foss Tighe; James Eastham; Raymond C Rosen Journal: BMC Med Inform Decis Mak Date: 2010-06-17 Impact factor: 2.796